Cefadroxil Anhydrous

Autoimmune Disease

Mayo ClinicSmall moleculePhase 4 / ApprovedActive

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 81/ 100

Competitive context

26 Active assets in the Autoimmune Disease cohort.

Asset / Sponsor	Phase	Rating
Total Glucosides Of Paeony West China Hospital	Phase 4	BB
Ursodeoxycholic Acid West China Hospital	Phase 4	BB
Cyclophosphamide The Children's Hospital of Zhejiang University School of Medicine	Phase 2	B
Cephalexin Mayo Clinic	Phase 4	B
Human Immunoglobulins University of Cambridge	Phase 3	B

View all 35 →

Same molecule, other indications

Cefadroxil Anhydrous is also rated in:

periprosthetic joint infectionActive

BB

Indicative · Phase 4

65 / 100

methicillin-susceptible staphylococcus aureus infectious diseaseActive

BB

Indicative · Phase 4

65 / 100

methicillin-resistant staphylococcus aureus infectious diseaseActive

BB

Indicative · Phase 4

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.